Long COVID: A growing problem in need of intervention

Bjørn Blomberg, Rebecca Jane Cox, Nina Langeland, Bjørn Blomberg, Rebecca Jane Cox, Nina Langeland

Abstract

The number of people who have survived COVID-19 is overwhelming-official figures approach half a billion. Thus, any long-term consequences in COVID-19 survivors could have a huge impact on public health and on healthcare services in the coming months and years, with potentially 100 million individuals affected.

Conflict of interest statement

The authors declare no competing interests.

© 2022 The Author(s).

References

    1. Blomberg B., Mohn K.G., Brokstad K.A., Zhou F., Linchausen D.W., Hansen B.A., Lartey S., Onyango T.B., Kuwelker K., Sævik M., et al. Bergen COVID-19 Research Group Long COVID in a prospective cohort of home-isolated patients. Nat. Med. 2021;27:1607–1613.
    1. Huang C., Huang L., Wang Y., Li X., Ren L., Gu X., Kang L., Guo L., Liu M., Zhou X., et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397:220–232.
    1. Geense W.W., Zegers M., Peters M.A.A., Ewalds E., Simons K.S., Vermeulen H., van der Hoeven J.G., van den Boogaard M. New Physical, Mental, and Cognitive Problems 1 Year after ICU Admission: A Prospective Multicenter Study. Am. J. Respir. Crit. Care Med. 2021;203:1512–1521.
    1. Thakur K.T., Miller E.H., Glendinning M.D., Al-Dalahmah O., Banu M.A., Boehme A.K., Boubour A.L., Bruce S.S., Chong A.M., Claassen J., et al. COVID-19 neuropathology at Columbia University Irving Medical Center/New York Presbyterian Hospital. Brain. 2021;144:2696–2708.
    1. Edén A., Kanberg N., Gostner J., Fuchs D., Hagberg L., Andersson L.M., Lindh M., Price R.W., Zetterberg H., Gisslén M. CSF Biomarkers in Patients With COVID-19 and Neurologic Symptoms: A Case Series. Neurology. 2021;96:e294–e300.
    1. Dahl E.H., Mosevoll K.A., Cramariuc D., Vedeler C.A., Blomberg B. COVID-19 myocarditis and postinfection Bell’s palsy. BMJ Case Rep. 2021;14:20210111.
    1. Phetsouphanh C., Darley D.R., Wilson D.B., Howe A., Munier C.M.L., Patel S.K., Juno J.A., Burrell L.M., Kent S.J., Dore G.J., et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat. Immunol. 2022;23:210–216.
    1. Le Bon S.D., Konopnicki D., Pisarski N., Prunier L., Lechien J.R., Horoi M. Efficacy and safety of oral corticosteroids and olfactory training in the management of COVID-19-related loss of smell. Eur. Arch. Otorhinolaryngol. 2021;278:3113–3117.
    1. Bergwerk M., Gonen T., Lustig Y., Amit S., Lipsitch M., Cohen C., Mandelboim M., Levin E.G., Rubin C., Indenbaum V., et al. Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. N. Engl. J. Med. 2021;385:1474–1484.
    1. Antonelli M., Penfold R.S., Merino J., Sudre C.H., Molteni E., Berry S., Canas L.S., Graham M.S., Klaser K., Modat M., et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect. Dis. 2022;22:43–55.
    1. Ayoubkhani D., Bermingham C. Coronavirus (COVID-19) vaccination and self-reported long COVID in the UK. 2021. Office for National Statistics (UK), October 25, 2021.
    1. Cohn B.A., Cirillo P.M., Murphy C.C., Krigbaum N.Y., Wallace A.W. SARS-CoV-2 vaccine protection and deaths among US veterans during 2021. Science. 2022;375:331–336.
    1. Taquet M., Dercon Q., Harrison P.J. Six-month sequelae of post-vaccination SARS-CoV-2 infection: a retrospective cohort study of 10,024 breakthrough infections. medRxiv. 2022 doi: 10.1101/2021.10.26.21265508. Preprint at.
    1. Scherlinger M., Pijnenburg L., Chatelus E., Arnaud L., Gottenberg J.E., Sibilia J., Felten R. Effect of SARS-CoV-2 Vaccination on Symptoms from Post-Acute Sequelae of COVID-19: Results from the Nationwide VAXILONG Study. Vaccines (Basel) 2021;10:20211230.
    1. Boglione L., Meli G., Poletti F., Rostagno R., Moglia R., Cantone M., Esposito M., Scianguetta C., Domenicale B., Di Pasquale F., Borrè S. Risk factors and incidence of long-COVID syndrome in hospitalized patients: does remdesivir have a protective effect? QJM. 2022;114:865–871.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever